# Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

> **NCT03542877** · PHASE2 · COMPLETED · sponsor: **Academic Thoracic Oncology Medical Investigators Consortium** · enrollment: 44 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Oral Tablet: Cabozantinib

## Key facts

- **NCT ID:** NCT03542877
- **Lead sponsor:** Academic Thoracic Oncology Medical Investigators Consortium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2020-10-19
- **Final completion:** 2022-03-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03542877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03542877, "Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03542877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*